Drug Trial Radar · NCT05836753
Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy
Last checked: Nov 20, 2026Latest source record: Jul 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
May 7, 2023
Primary completion
Nov 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Beijing Tiantan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Neurodawn Pharmaceutical Co., Ltd.
- First posted
- May 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study was to evaluate the efficacy and safety of Sarecycline versus placebo in the treatment of microcirculation dysfunction after reperfusion therapy in patients with large vessel occlusion stroke.
Conditions
- Ischemic Stroke, Acute
Interventions
Sarecycline TabletDrug
Each tablet contained 100 mg of Sarecycline.
Placebo tablets of Sarecycline tabletsDrug
Each tablet contained 0 mg of Sarecycline.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes of NIHSS score between baseline and at 7 days after randomization.Time frame: at 7 days after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.